Chemical formula: C₁₄H₁₉N₅O₄S Molecular mass: 353.4 g/mol PubChem compound: 24764487
Gefapixant is a selective antagonist of the P2X3 receptor. P2X3 receptors are ATP-gated ion channels found on sensory C fibres of the vagus nerve in the airways. C fibres are activated in response to inflammation or chemical irritants. Blockade of ATP signalling through P2X3 receptors reduces excessive sensory-nerve activation and excessive cough induced by extracellular ATP.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| R05DB29 | R Respiratory system → R05 Cough and cold preparations → R05D Cough suppressants, excl. combinations with expectorants → R05DB Other cough suppressants | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| LYFNUA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Gefapixant is an active ingredient of these brands:
Croatia (HR)
Estonia (EE)
Ireland (IE)
Italy (IT)
Japan (JP)
Lithuania (LT)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
